Full-Time

Senior Associate Scientist

Viral Vaccines & Immunology

Posted on 9/26/2025

Deadline 10/9/25
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$66.5k - $110.9k/yr

+ Bonus

New City, NY, USA

In Person

Category
Biology & Biotech (4)
, , ,
Required Skills
Data Analysis
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • BA/BS with at least 2 to 4 years of experience or MBA/MS with 0 to 3 years of experience
  • Hands-on experience in cell culture and cell-based assays
  • Proficiency in using relevant software for data analysis
  • Fundamental laboratory skills, including quantitative-PCR, molecular biology, western blotting, biochemical assays, and tissue processing
  • Strong background in experimental design and result interpretation
  • Effective verbal and written communication skills
  • Proficiency in using personal computers for word processing, Excel, PowerPoint, and scientific software
Responsibilities
  • Conduct various assays to monitor immune responses elicited by vaccine candidates and document laboratory work involving bio-functional assays thoroughly
  • Maintain cell lines, process red blood cells weekly, and prepare samples for testing, assisting with molecular and virology work
  • Generate plasmid constructs for RNA and reverse genetic virus stocks, optimizing RNA vaccines
  • Ensure compliance with SOP guidelines, cGLP, and/or cGMP guidelines, and execute qualifications and validations of new instruments and custom methods
  • Contribute to work group goals, collaborate with team members, and participate as a team member
  • Prioritize work to meet project deadlines, apply technical skills to assignments, and organize work according to departmental priorities
  • Choose between alternatives to solve moderately complex problems, follow procedures with general instructions, and work under moderate supervision with regular review
  • Collaborate with the Primary Pharmacology Group to ensure alignment around assay technology selection, assay quality criteria, and validation requirements
  • Interact with external vendors to obtain quotes and purchase reagents for clinical testing, and manage manual and robotic sample preparation
  • Identify and report experimental problems, troubleshoot causative factors, implement necessary corrections after discussing with the supervisor, and train other analysts on established technologies while managing direct reports
Desired Qualifications
  • Hands-on experience with mammalian cell culture and flow cytometry
  • Practical knowledge in cell culture techniques and flow cytometry analysis
  • Experience in drug discovery processes
  • Expertise in maintaining and manipulating cell lines for experimental purposes
  • Proficiency in analyzing cell populations and their characteristics
  • Strong problem-solving skills
  • Ability to work collaboratively in a team environment
  • Excellent organizational and time management skills

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Oncology biosimilars grow 52% operationally in Q1 2026 amid high-margin expansion.
  • ELREXFIO Phase 3 data supports earlier multiple myeloma treatment positioning.
  • PF-08653944 advances to 10 Phase 3 trials in 2026 with 9.6mg dose.

What critics are saying

  • Eliquis patent expires 2028, generics erode $6B annual revenue 70% in 12 months.
  • Ibrance generics launch 2027, slash $5B sales 60-80% within 18 months.
  • Danuglipron discontinued April 2025 after liver injury in early trials.

What makes Pfizer unique

  • VEPPANU secures FDA approval as first PROTAC therapy for ESR1-mutated breast cancer.
  • VYNDAMAX patent settlements extend US exclusivity to June 2031.
  • PF-08653944 achieves 12.3% placebo-adjusted weight loss monthly in Phase 2b VESPER-3.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Company News

Pfizer
May 4th, 2026
Esperion Therapeutics Completes $22.75 M Series A Financing | Pfizer

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich

Yahoo Finance
Apr 9th, 2026
Pfizer beats Q4 revenue estimates by 5.5% as branded pharma sector faces mixed earnings

Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.

Yahoo Finance
Apr 7th, 2026
Pfizer stock seen as undervalued buy despite pipeline growth and strategic acquisitions

Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.

Yahoo Finance
Apr 6th, 2026
Pfizer shares climb 7.1% in six months as organic revenue grows 10.1% annually

Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.

Yahoo Finance
Mar 30th, 2026
Pfizer shares up 25% since Jim Cramer said 'pass' on Mad Money

Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.

INACTIVE